YM Bio says Japanese, Korean nimotuzumab licencees begin enrolment for trial
finanznachrichten.de
01-Oct-2008
        

LONDON (Thomson Financial) - YM BioSciences Inc. said two of its licensees for nimotuzumab, Daiichi Sankyo Co. Ltd. and Korea-based Kuhnil Pharmaceutical Co., have commenced enrolment in an 80-patient Phase... [read full story]                    

Add Comment
View all news articles about*:
BioSciences Korea North South Thomson
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies